Crucell « Terug naar discussie overzicht

Sanofi, Sanofi en nog eens Sanofi

785 Posts, Pagina: « 1 2 3 4 5 6 ... 9 10 11 12 13 14 15 16 17 18 19 ... 36 37 38 39 40 » | Laatste

Omlaag ↓

[verwijderd] 28 april 2009 11:42

die overname komt morgen let maar op! gisteren 2 miljoen stuks en dat is niet alleen door de griep.

flosz 28 april 2009 11:44

quote:
munckf schreef:
Even in jullie herinnering roepen: morgen Q1 cijfers. Altijd een mooi moment voor aankondigingen.

Als in “we zijn er klaar voor…..but it won't happen fast”.
www.poconorecord.com/apps/pbcs.dll/ar...

aossa 28 april 2009 11:51

quote:
flosz schreef:
[quote=munckf]
Even in jullie herinnering roepen: morgen Q1 cijfers. Altijd een mooi moment voor aankondigingen.
[/quote]
Als in “we zijn er klaar voor…..but it won't happen fast”.
www.poconorecord.com/apps/pbcs.dll/ar...

New facility in Mexico ...

The construction of this facility in Ocoyoacac, where sanofi-aventis already has a manufacturing site, represents an investment of 100 million Euros. The goal is to produce up to 25 million annual doses of flu seasonal vaccines for the Mexican market, with delivery of the first doses planned for 2012. This facility will be built in accordance with standards which will allow switching from the seasonal production of flu vaccines to pandemic flu vaccines, if need be.

en.sanofi-aventis.com/at-a-glance/new...

[verwijderd] 28 april 2009 12:05

quote:
Goeroe1980 schreef:
die overname komt morgen let maar op! gisteren 2 miljoen stuks en dat is niet alleen door de griep.

Ben jij het broertje van B-B , die de overname al VOOR 1 april zag gebeuren, met zekerheidsgarantie.
Overname is uitgesloten, allemaal een spel, van.....`?
Vul in en kleur de plaatjes.

aossa 28 april 2009 12:30

Sanofi Pasteur: 4 Months To Make 1st Human Swine Flu Vaccine

PARIS -(Dow Jones)- The world's leader manufacturer of human vaccines Sanofi Pasteur, a unit of pharmaceutical giant Sanofi-Aventis (SNY), Monday said it would take around four months to produce its first vaccine against the human form of the swine influenza.

Sanofi Pasteur "has been monitoring the situation concerning human cases of H1N1 swine influenza virus infection reported in Mexico and the U.S., in coordination with the World Health Organization and other health authorities," a company spokesman said.

The vaccines manufacturer "stands ready to assess its capabilities to support public health efforts, should the WHO and other health authorities request support from influenza vaccine manufacturers," the spokesman added.

But so far, Sanofi Pasteur hasn't been asked to start developing a human vaccine against swine flu, he said.

www.nasdaq.com/aspx/stock-market-news...

[verwijderd] 29 april 2009 08:55

(Citaat uit Q1 rapport)
Transformation of sanofi-aventis

- Significant boost to our generics business, with 2008 proforma net sales of
approximately €1.2 billion due to the acquisitions of Zentiva, Medley and Kendrick
- Updating of our R&D portfolio: refocusing on the most promising projects, and
acceleration of external R&D alliances
- Acquisition of BiPar Sciences, Inc., strengthening our oncology R&D portfolio with the
addition of the PARP inhibitor BSI-201 and demonstrating our strong commitment in
oncology

Lijkt me alle reden voor de aandeelhouders om eens te informeren naar de voortgang van de vaccins-acquisities, want daar wil het allemaal nog niet zo opschieten. Terwijl dat toch een zeer wezenlijk onderdeel van de strategie is!

flosz 29 april 2009 09:22

Rabies en flu staan gezellig bij elkaar in Phase II.
P. 20.
en.sanofi-aventis.com/binaries/200904...

[verwijderd] 29 april 2009 09:51

Sanofi-Aventis boekt winstgroei 19% in eerste kwartaal

AMSTERDAM (Dow Jones)--Sanofi-Aventis SA heeft in het eerste kwartaal van 2009 de nettowinst met 19zien stijgen tot EUR1,58 miljard, geholpen door een striktere kostenbeheersing. Het Franse farmaceutische concern kondigde tevens aan veertien projecten in de ontwikkelingspijplijn te staken. Ook bevestigde het bedrijf de winstverwachting voor 2009.

De aangepaste nettowinst exclusief items steeg in het afgelopen kwartaal met 16tot EUR2,18 miljard. De winst kwam daarmee hoger uit dan de EUR1,91 miljard die analisten hadden voorzien. Sanofi-Aventis zag de netto-omzet in het afgelopen kwartaal met 2,5toenemen tot EUR7,11 miljard.

Voor 2009 handhaaft het op drie na grootste farmaceutische concern ter wereld de verwachting van een groei van de aangepaste winst per aandeel exclusief items van ten minste 7 tegen constante wisselkoersen.

Met betrekking tot mogelijke overnames stelt bestuursvoorzitter Chris Viehbacher dat het bedrijf blijft kijken naar interessante overnamekandidaten, maar dat er momenteel geen actieve gesprekken worden gevoerd.

Het aandeel Sanofi-Aventis noteert woensdagochtend rond 09.45 uur ruim 1,4hoger op EUR42,22, na publicatie van de kwartaalresultaten.

- Door Martijn Mom; Dow Jones Nieuwsdienst; 31-20-5715 201; martijn.mom@dowjones.com

(END) Dow Jones Newswires

April 29, 2009 03:48 ET (07:48 GMT)

bilbo3 29 april 2009 09:57

maar er staat meer!!!

van belang voor Quinvaxem: (goed en slecht nieuws!!)
• In Phase III, saredutant is discontinued on the basis of results from the study in association with
escitalopram in depression, AVE5530 is halted in hypercholesterolemia due to insufficient efficacy,
and the rights to TroVax® are returned to Oxford BioMedica. As regards vaccines, resources in the
intercontinental zone will be reallocated to the hexavalent vaccine Hexaxim® (DTP-HepB-Polio-Hib),
with the UnifiveTM pentavalent project (DTP-HepB-Hib) discontinued.

En ten aanzien van West Nile, de samenwerking met Acambis:
In addition, we will decide in the next few months whether or not to continue developing four products
(AVE1625, xaliprodene, idrabiotaparinux and West Nile virus vaccine), primarily on the basis of results from
clinical trials currently under way.

[verwijderd] 29 april 2009 10:00

quote:
straksa schreef:
Sanofi-Aventis boekt winstgroei 19% in eerste kwartaal

Met betrekking tot mogelijke overnames stelt bestuursvoorzitter Chris Viehbacher dat het bedrijf blijft kijken naar interessante overnamekandidaten, maar dat er momenteel geen actieve gesprekken worden gevoerd.

Handig geformuleerd: geen actieve gesprekken. Passieve gesprekken kunnen immers snel actief worden

aossa 29 april 2009 10:52

quote:
straksa schreef:
Met betrekking tot mogelijke overnames stelt bestuursvoorzitter Chris Viehbacher dat het bedrijf blijft kijken naar interessante overnamekandidaten, maar dat er momenteel geen actieve gesprekken worden gevoerd.

Lijkt mij dat bij een actief gesprek er over geld gesproken wordt, bij een passief gesprek is dat (nog) niet aan de orde, eerder onderzoekend. Maar waar rook is, is vuur en dat geldt ook voor een passief laaiend vuurtje ...

Of hoe moet ik me het anders voorstellen ?

ved 29 april 2009 10:57

Uit Interview Viehbacher:

EBM : The pharma sector seems to be bubbling with M&A activity lately. What is your strategy and vision today regarding M&A, in particular what are your views when it comes to mega-mergers ?

CW : We’ve been very upfront about the fact that, although we have some very strong opportunities in our pipeline — and we just talked about Multaq, we can talk about our vaccine products — I’ve also been very clear that we don’t have enough new products in our pipeline to really compensate for the products that we will lose when products like Plavix go off-patent in 2012. Therefore, we need to be pushing organic growth, which we’re doing, but it also means that we’ll be looking to acquire companies that can build the platforms of growth that we have identified : vaccines, OTCs, generics, as well as of course our own pharma business. So for us, the most important thing is what businesses we can acquire that we think we can do better with, that we think that we can create value with. And we’ve created a team under Laurence Debroux, a dedicated team, under the Chief Strategic Officer, that is looking at any number of deals. I think we’ve looked at something like 75 or 76 things this quarter alone. So that’s the process that we’re going to pursue.

www.eurobusinessmedia.com/transcript....

aossa 29 april 2009 13:36

Sanofi pulls plug on four Ph III drugs
By Gareth Macdonald, 29-Apr-2009

Sanofi-Aventis has halted development of four Phase III drugs in a “rigorous” pre-patent loss pipeline review that has also seen it drop four Phase II candidates and six Phase I projects.

The French drugmaker, which posted a 15 per cent leap in Q1 operating profit beating analyst estimates, said it is refocusing its R&D efforts according to both scientific and commercial criteria.

The four abandoned Phase III candidates include the antidepressant saredutant and the blood pressure drug AVE5530, which failed to demonstrated sufficient efficacy in clinical studies.

************************************************************************************************************
Sanofi has also halted work on its Phase III combination vaccine Unifive in favour of continuing the development of Hexaxim which, in addition to diphtheria, hepatitis B and haemophilus influenzae type B, also protects against polio.
************************************************************************************************************

RetinoStat replaces Trovax in Oxford deal
The final Phase III drug being dropped by Sanofi is the cancer vaccine Trovax, which has been handed back to UK headquartered development partner Oxford Biomedica along with a $16.5m (€12.5m) termination payment.

While this is obviously a blow for the UK firm, the companies will continue to work together to develop treatments for eye diseases using Oxford's LentiVector gene delivery technology.

The firms’ new agreement includes an age-related macular degeneration (AMD) treatment called RetinoStat which, given yesterday’s deal between Pfizer and UCL and existing products like Lucentis, may see eye disease emerge as a major battle ground in the post CV blockbuster era.

The cuts leave Sanofi with a pipeline of 51 drugs, 21 of which are under regulatory review or in Phase III trials. The firm said that it may also pull four more products, AVE1625, xaliprodene, idrabiotaparinux and a West Nile virus vaccine, in the next few months.

CEO Christopher Viebacher, who has sped up Sanofi’s pipeline review since taking charge in December, said that the firm will aim to increase the percentage of biotech products in its pipeline from 14 to 25 per cent over the next three years.

Mega mergers back on Sanofi’s agenda?
Viebacher also restated the Sanofi’s acquisition policy, telling Bloomberg that “We are looking at everything, all sizes of transactions. The filter is not the size. The filter is where we see growth opportunities.”

This contrasts with comments Viebacher made in February when he eschewed mega-merger strategies like Pfizer’s acquisition of Wyeth in favour of purchases in the $5-$15bn range.

Indeed, despite the fact that Sanofi’s purchases this year, which include Kendrick, Medley and BiPar, have all been within or below this limit some observers have speculated that the firm is on the look out for bigger acquisitions.

A report by Urch Publishing released earlier this week argued Sanofi is one of the best placed Big Pharma’s for a mega deal and suggested Bristol-Myers Squibb (BMS) and Bayer as potential targets.

www.in-pharmatechnologist.com/content...

aossa 29 april 2009 13:42

First Quarter 2009 Results
April 29, 2009: live audio webcast of the conference at 2:30 p.m. CET

en.sanofi-aventis.com/investors/event...

Interview with Chris Viehbacher
en.sanofi-aventis.com/events/2009_1st...

josti5 29 april 2009 14:19

'The filter is not the size. The filter is where we see growth opportunities.” '

En de goede man blijft maar herhalen, dat-ie Crucell wil inlijven...

[verwijderd] 29 april 2009 14:26

even wachten op de 14
mijn wagen is leeg

aossa 29 april 2009 14:34

Presentation:
clients.dbee.com/sanofi/20090429/en/t...

[verwijderd] 29 april 2009 14:43

quote:
josti5 schreef:
En de goede man blijft maar herhalen, dat-ie Crucell wil inlijven...

Cynisch?

aossa 29 april 2009 19:42

quote:
josti5 schreef:
'The filter is not the size. The filter is where we see growth opportunities.” '

En de goede man blijft maar herhalen, dat-ie Crucell wil inlijven...

Crucell Remains Takeover Target, expecially now.
We hope to see CRXL over $40 before summer. Not far from valuations we heard when Wyeth thought about potential combination of the two companies.

www.entendance.com/forums/viewtopic.p...

flosz 29 april 2009 19:57

quote:
aossa schreef:
Crucell Remains Takeover Target, expecially now.
We hope to see CRXL over $40 before summer. Not far from valuations we heard when Wyeth thought about potential combination of the two companies.

www.entendance.com/forums/viewtopic.p...

= imo gelijk aan een hieperdepiep post zonder daadwerkelijke inhoud van het maakt niet zoveel uit wie op dit forum....zoiets als de postjes van willemn, maar dan anders.

785 Posts, Pagina: « 1 2 3 4 5 6 ... 9 10 11 12 13 14 15 16 17 18 19 ... 36 37 38 39 40 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 937,58 -1,00 -0,11% 21 feb


Germany40^	22.179,70	-0,60%
BEL 20	4.405,39	+0,82%
Europe50^	5.441,66	-0,61%
US30^	43.424,20	0,00%
Nasd100^	21.616,30	0,00%
US500^	6.014,32	0,00%
Japan225^	38.152,90	0,00%
Gold spot	2.935,70	0,00%
EUR/USD	1,0460	-0,36%
WTI	70,19	0,00%